Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label study of fosmanogepix for invasive mold infections
2024-516216-16-00Phase 3Authorised
- Sponsor
- Basilea Pharmaceutica
- Start
- Feb 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 14
01
Overview
Phase 3, open-label trial of fosmanogepix in Invasive Mold Infections (IMIs), aspergillosis, fusariosis and 2 more (2 cohorts), sponsored by Basilea Pharmaceutica. Primary endpoint: Day 42 all-cause mortality rate. Planned start Feb 2026; status: authorised.
02
Drugs
fosmanogepix
03
Conditions
Invasive Mold Infections (IMIs)aspergillosisfusariosislomentosporiosismucormycosis
Beyond the preview
Go deeper on 2024-516216-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516216-16-00.